Rocatinlimab is a Monoclonal Antibody owned by Kyowa Kirin, and is involved in 8 clinical trials, of which 5 were completed, 2 are ongoing, and 1 is planned.
Rocatinlimab acts by antagonizing OX40. It is mainly expressed in activated Tcells. OX40-OX40 ligand interaction promotes the survival of activated T cells and accelerates the formation of memory T cells. OX40 also has an important role to play in the reactivation of memory T cells. KHK-4083 by antgonizing OX40, down regulates the inflammatory mediators and reduces the disease condition.
The revenue for Rocatinlimab is expected to reach a total of $7.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Rocatinlimab NPV Report.
Rocatinlimab is under development for the treatment of atopic dermatitis. The drug candidate is a new molecular entity (NME). It is administered through intravenous and subcutaneous infusion. It is a monoclonal antibody and acts by targeting OX40. The drug candidate is based on POTELLIGENT antibody engineering technology. It was also under development for the treatment of moderate plaque psoriasis and ulcerative colitis .
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television and online media. Amgen is headquartered in Thousand Oaks, California, the US.
The company reported revenues of (US Dollars) US$25,979 million for the fiscal year ended December 2021 (FY2021), an increase of 2.2% over FY2020. In FY2021, the company’s operating margin was 29.4%, compared to an operating margin of 35.9% in FY2020. In FY2021, the company recorded a net margin of 22.7%, compared to a net margin of 28.6% in FY2020. The company reported revenues of US$6,652 million for the third quarter ended September 2022, an increase of 0.9% over the previous quarter.
Quick View – Rocatinlimab
|Highest Development Stage|